The hurdles of warfarin and the hurdles of clinical practice [1]

Stroke

Volumn 37, Issue 12, 2006, Pages 2867-

  Testa, Luca ^a   Trotta, Graziana ^a   Abbate, Antonio ^b   Agostoni, Pierfrancesco ^c   Biondi Zoccai, Giuseppe G L ^d  

^a CATHOLIC UNIVERSITY   (Italy)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MIDDELHEIM HOSPITAL   (Belgium)

^d IRCCS POLICLINICO SAN DONATO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; DABIGATRAN; WARFARIN; XIMELAGATRAN;

AGE; AGED; AGING; ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG RESPONSE; HEART ATRIUM FIBRILLATION; HIGH RISK POPULATION; HUMAN; LETTER; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; SECONDARY PREVENTION; STROKE;

ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; HUMANS; RISK FACTORS; WARFARIN;

EID: 33845386968     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000248206.73601.ae     Document Type: Letter

References (6)

1. Hylek EM, D'Antonio J, Evans-Molina C, Shea C, Henault LE, Regan S. Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke. 2006;37:1075-1080.
2. Testa L, Biondi-Zoccai GG, Dello Russo A, Bellocci F, Andreotti F, Crea F. Rate-control vs rhythm-control in patients with atrial fibrillation: a meta-analysis. Eur Heart J. 2005;26:2000-2006.
3. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, Halperin JL, Kay GN, Klein WW, Levy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Gregoratos G, Hiratzka LF, Jacobs AK, Russell RO, Smith SC Jr, Alonso-Garcia A, Blomstrom-Lundqvist C, de Backer G, Flather M, Hradec J, Oto A, Parkhomenko A, Silber S, Torbicki A. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. Circulation. 2001;104:2118-2150.
4. Gold-standard warfarin bests clopidogrel/aspirin combo in AF: ACTIVE-W. Available at: http://www.theheart.org. Accessed September 7, 2005.
5. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation. 1991;84:527-539.
6. AstraZeneca Decides to Withdraw Exanta™ (ximelagatran). Press release from AstraZeneca international, February 14, 2006. Available at: http://www.astrazeneca.com/pressrelease. Accessed February 15, 2006.